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Summary.-Two mouse monoclonal antibodies against the human osteogenic sar-
coma 791T were examined for their capacity to exert complement-dependent
cytotoxicity against a panel of human tumour cell lines. Cytotoxicity was most
evident against the immunizing tumour 791T although significant reactivity was
directed against other osteogenic sarcomas. In admixture, the 2 antibodies displayed
synergism in their cytotoxicity although this was only demonstrable with defined
ranges of antibody concentration. The cytotoxicity of these antibodies was dependent
upon the use of rabbit serum as complement and no tumour-cell lysis was produced
using human, guinea-pig or mouse serum complement. The more potent cytotoxic
antibody failed to modify the outgrowth of 791T tumour xenografts in immuno-
deprived mice even though localization of antibody at the tumour site has been
demonstrated (Pimm et al., 1982).
SINCE THE INTRODUCTION of hybridoma
technology (K6hler & Milstein, 1975),
monoclonal antibodies have been produced
which show preferential reactivity with
malignant cells, although their potential
as effective therapeutic agents has yet to
be realized (reviewed by Baldwin et al.,
1981). The powerful cytotoxicity of IgM
and IgG2 monoclonal antibodies in the
presence of complement suggests a direct
role for these antibodies in limiting tumour
development or controlling residual dis-
ease. Already, cytotoxic murine anti-
bodies have been prepared against a
number of human tumours, and thera-
peutic manipulations using the passive
administration of antibody have been
attempted in immunodeficient mice bear-
ing human tumour xenografts (Herlyn et
al., 1980; Herlyn & Koprowski, 1981) and
with leukaemia in mice (Bernstein et al.,
1980) and humans (Ritz et al., 1981;
Miller et al., 1981) with varying degrees
of success.
In preliminary tests, it was evident that
the 2 anti-human osteogenic sarcoma
monoclonal antibodies described by
Embleton et al. (1981a, b) exhibited com-
plement-dependent cytotoxicity against
the immunizing osteogenic sarcoma cell
line, 791T. In the present investigation,
the capacity of these antibodies to
mediate complement-dependent cytotoxi-
city against a panel ofosteogenic sarcomas
and other tumours has been evaluated
using a short-term 51Cr-release test. An
important aspect of this work was to
determine whether the anti-tumour cyto-
toxic reactions were demonstrable using
mouse and human sera as sources of
complement, since these antibodies have
therapeutic potential in model studies
withhumantumourxenograftsin immuno-
deprived mice or in patients.
MATERIALS AND METHODS
Cells-.Human tumour cell lines employed
as target cells in complement-dependent cyto-
toxicity assays included osteogenic sarcomas
(791T, 788T, 278T and 20S), prostate carcin-
oma (EB33), lung carcinoma (A549) and2M. R. PRICE, M. V. PIMMI AND R. W. BALDWIN
ovarian carcinoma (PAl). Cell lines were
grown as monolayers in Eagle's minimum
essential medium supplemented with 10%
(v/v) fetal calf serum (FCS). Human peri-
pheral blood mononuclear cells were prepared
from heparinized blood by density-gradient
centrifugation upon Ficoll-Triosil (Lympho-
prep-Flow Laboratories, Irvine, Scotland).
Cells, suspended at 2 x 106/ml in a 1/200
dilution of PHA (Wellcome Reagents Ltd,
London) in RPMI 1640 containing 5% FCS
5 x 10-5M 2-mercaptoethanol and gentamycin
(50 u/ml), were dispensed in Costar 24 Well
Cluster Plates (A. R. Horwell, London) at
1 mg/ml. The preparation of PHA-blasts was
harvested after incubation at 37°C for 48 h
and washed twice by centrifugation in Eagle's
HEPES medium containing 5% FCS.
Anti-osteogenic sarcoma monoclonal anti-
bodies.-Hybridomas 791T/36 Clone 3 and
791T/48 Clone 15 (Embleton et al., 1981a, b)
provided the source of antibody in super-
natants from in vitro cultures.
Antibody was isolated from culture super-
natants by passage through a 5 ml packed bed
volume of Sepharose-linked Protein A (Phar-
macia, Uppsala, Sweden) at 50ml/h. The non-
bound fraction was discarded and the column
was extensively washed with phosphate-
buffered saline (PBS) pH 7-3, containing
0.02% (w/v) sodium azide. This column was
then connected to a column of Sephadex G25
(Pharmacia) and elutionl of the bound anti-
body was achieved by application of 3M
NaSCN. The eluted protein peak separated
from the NaSCN by Sephadex G25 gel filtra-
tion was concentrated by positive-pressure
membrane ultrafiltration using a PM1O
Amicon membrane (Amicon, HighWycombe).
Separate Sepharose-Protein A columns were
used for the purification of anti-791T/36 and
anti-791T/48 antibodies in order to avoid
cross-contamination. The recovery of purified
anti-791T/36 and anti-791T/48 antibodies was
16-8 + 8-0 and 4-3 + 2-9 jig/ml respectively of
original hybridoma supernatants. Antibody
concentrations were determined using the
protein assay ofLowry orspectrophotometric-
allv assuming an E'% of 14-3 (Hudson &
Hay, 1980). Both monoclonal antibodies
were determined as belonging to the mouse
IgG2b subclass as defined in immunodiffusion
tests using mouse immunoglobulin-typing
antisera (Miles Laboratories, Stoke Poges,
U.K.).
Anti-HLA-A, B, C (shared determinant)
Clone W6/32 HL monoclonal antibody was
obtained as serum/ascites fluid (Ig content
2 mg/ml) from Sera-Lab. (Crawley Down,
Sussex).
Complement.-Lyophilized rabbit serum
(Buxted Rabbit Co. Ltd, Sussex) was re-
constituted with distilled water immediately
before use. Guinea-pig (Dunkin-Hartley
strain) serum, CBA/Ca mouse serum and
human serum from laboratory personnel was
stored at - 70°C until use.
Complement-dependent cytotoxicity assay.-
The complement-dependent cytotoxicity of
anti-791T monoclonal antibodies was mea-
sured using a 2 h 51Cr-release assay (Price,
1978). Briefly, tumour target cells were
labelled with 125,tCiNa251CrO4 (Radiochemi-
cal Centre, Amersham) for 60 min at 37°C in a
volume of 0 5-1 0 ml Eagle's HEPES con-
taining 5% FCS. After washing cells 3 x by
centrifugation, cells were aliquoted (50 ,ul
containing 104 cells) in quadruplicates into
round-bottomed Sterilin M24A microtest
plates which contained media, diluted heat-
inactivated (56°Cfor 1 h) seraordilutedmono-
clonal antibody preparations at 100 ,ul/well.
As source of complement, rabbit, mouse,
human or guinea-pig serum (100 ,ul aliquots)
was added to each well at concentrations
which had been predetermined for each cell
line to be non-toxic for the cells alone. All
dilutions were performed using Eagle's
HEPES medium containing 5% FCS. After
incubation at room temperature for 2 h, plates
were centrifuged at 280 g for 10 min, and
lOO1I aliquots of the supernatants were col-
lected and counted for radioactivity using an
LKB-Wallac gamma counter. The percentage
release of 51Cr was calculated for each test
sample and medium control samples. The
maximum percentage release of 51Cr ( >90%
with all cell lines) was determined by the
addition of 1% sodium dodecyl sulphate to
labelled target cells, and the percentage
release in samples exposed to medium alone
did not exceed 15%. The percentage cyto-
toxicity values were calculated as [(% 51Cr
release in test samples - % 51Cr release in
medium control samples)/(maximum % 51Cr
release - % 51Cr release in medium control
samples)] x 100%.
Mice andxenografts.-CBA/Camice (Bantin
and Kingman, Hull) were thymectomized at
3-4 weeks ofage and 3-6 weeks later received
9 Gy whole-body y-irradiation from a 60Co
source. The lethal effect of irradiation was
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prevented by i.p. injection of 200 mg/kg
cytosine arabinoside (Cytosar, Upjohn, Craw-
ley) 2 days before irradiation (Steel et al.,
1978). Xenograft growths were initiated by
s.e. injection of 106-107 tumour cells har-
vested withl trypsin from in vitro cultures
and washed in serum-free medium. Mice
were maintained on sterile bedding with
sterilized food and water and held in isolator
cabinets (Vickers Pathoflex Isolator, Basing-
stoke). They were exsanguinated by heart
puncture, and the serum was collected and
stored at -20°C. Mice were found to be free
of macroscopically visible thymic remnants
at the time of blood collection.
RESULTS
(omplement-dependent cytotoxicity of anti-
human osteogenic sarcoma 791T monoclonal
antibodiesfor various target tumour cell lines
The anti-human osteogenic sarcoma
monoclonal antibodies anti-791T/36 and
anti-791T/48 belong to the IgG2b subclass
with mouse K light chain. Murine IgG2b
antibodies are complement-fixing (Stan-
worth & Turner, 1978) and the data in
Fig. I confirm that both antibodies
mediate complement-dependent cytotoxi-
city against 791T target cells employing
rabbit serum as the source of complement.
At the highest antibody concentration
tested (125 .tg/ml), anti-791T/36 mono-
clonal antibody reacted strongly with the
4 osteogenic sarcoma cell lines 791T, 788T,
278T and 208, and the cross-reactive
prostate carcinoma cell line EB33. This
antibody displayed no reactivity for the
cell lines A549 (lung carcinoma) and PAl
(ovarian carcinoma). At the lower anti-
body concentrations, down to 1 ,ug/ml, it
was evident that the cell lines 791T and
788T were the most susceptible to anti-
body-induced, complement-dependent cell
lysis.
The other anti-human osteogenic sar-
coma 791T monoclonal antibody, anti-
791T/48, exhibited much lower reactivity
in these tests although significant levels of
cytotoxicity were recorded against the
line 791T. This finding is in accord with
those of preliminary experiments in which
41
40
20S
(C' - 1/10)
20 -
125 25 5 10
788T
{C' - 1/10)
125 25 5 1 0
278T
C'- 1/20)
A-
125 25 5 1 0
\ EB33 A549
\C' - 1/5) (C' - 1/5)
125 25 5 1 0 125 25 5 1 0
20 PA I
(C' - 1/10)
0
125 25 5 1 0
ANTIBODY CONCENTRATION Ipg//ml)
FIG. 1. Complement-dependent cytotoxicity
of anti-osteogenic sarcoma 791T mono-
clonal antibodies against various human
tumotur cell lines. The % cytotoxicities of
anti-79lT/36 an(i anti-791T/48 antibodies
in tloe presence ofrabbit serum complemenit
(C'), at the dilution stated in parentheses,
are in(licated by solid circles and squares,
respectively. In the presence of heat-
inactivated (56°C for 60 mimi) complement,
their cytotoxicities are indicated by open
circles and squares, respectively. The cyto-
toxicities of complement alone and beat-
inactivated complement alone arepresentedl
by solid and open triangles, respectively.
Thie s.d. on all cytotoxicity values > 5%
(vitli the exception of one (letermination)
clid not exceed 1000 of the mean value.
anti-791T/48 hybridoma supernatants
failed to induce complement-dependent
cytotoxicity. In such supernatants, anti-
body concentrations are approximately
5 ,ug/ml, which clearly is insufficient for
demonstrable cytotoxicity (Fig. 1).
All cytotoxic reactions against the
various cell lines in Fig. 1 were dependent
upon the presence of active rabbit serum
complement, and all cytotoxic values
determined in the presence of heat-
inactivated complement (56TC for 1 h) were
in the range -0 5 to 1 9% cytotoxicity.
603
I-
x
oW6M. R. PRICE, M. V. PIMM AND R. W. BALDWIN
TABLE I.-Synergistic antibody-mediated, complement-dependent cytotoxicity ofanti-791T/
36 and anti-791T/48 monoclonal antibodies for osteogenic sarcoma 791T target cells
% cytotoxicity (mean+s.d.)
Concentration ofanti-791T/36 monoclonal antibody (ug/ml)
t
0
0 0-8+0-5*
(0 1±0 7)t
0-2 1-1+0-5
1*1
1 0*0+0-2
0 04 0-2
0 0+0-4 0-0+1-6
004:
0 7+0 5
1*1
0-8+1-2
0.0
20+0-7
(04 4+06)
1
1-6
0-0 0.0
5 25
3-2+0-6 13-1+2-3 42-6+1-7
(1-0+0-7)
3-2 13-1 42-6
4 7+0 5 16-0+1-6 45-5+2-0
125
64-7 + 22
(0 8± 8)
64-7
75-4+2-6
Z-l 4-3 14-2 43-7 65-8
+0-6 5-8+0*9 14-6+0 7 440+_0-6 76-8+4*3
(0 1+0 8)
0-0 3-2 13-1 42-6 64-7
5 2-1+0-9 09+_1-2 2-0+0 7 6-6+1-0 17-9+2-5 41-1+3-2
(-0 1±0 4)
2-1 2-1 2-1 5-3 15-2 44-7
25 1 5+0-5 2-3+0-7 3-9+1*8 11-4+0-5 29-1+1-7 50-2_2-1
(-0.5+0 1)
1-5 1-5 1-5 4-7 14-6 44-1
125 7-6+1-1
(0 3+0 8) 7-6
76-9 +43
66-8
81 -1+6-6
66-2
21-1+2-9 300+_1-6 42-6+2-6 61-5+3-1 700+4-4 79B5+ 11
7 6 7-6 10-8 20-7 50-2 72-3
* Upper figures represent the % cytotoxicities of the 2 antibodies in admixture, in the presence of rabbit
serum complement (final dilution-1/10).
t Figures in parentheses represent the % cytotoxicities of the 2 antibodies in admixture, in the presence
of heat-inactivated rabbit serum complement (final dilution-1/10).
t Figures in italics represent the sum of the % cytotoxicities of the 2 antibodies when tested individually.
The pattern of reaction of the 2 mono-
clonal antibodies with these cell lines
parallels those demonstrated using the
125I-Protein A cell-binding assay (Emble-
ton et al., 1981a, b).
Synergistic, complement-dependent cytotoxi-
city of anti-791T monoclonal antibodies
Anti-791T/36 and anti-791T/48 mono-
clonal antibodies in admixture exhibited
synergistic killing of 791T cells when low
concentrations of anti-791T/36 antibody
(0-04-5 ug/ml) were present with higher
concentrations of anti-791T/48 (25 and
125 ug/ml) (Table I). Taking one example,
when incubation mixtures contained anti-
791T/36 and anti-791T/48 antibodies at 1
and 125 ,ug/ml respectively, the cytotoxi-
city measured (42-6 + 2.6%) was about 4 x
the sum (10.8% cytotoxicity) of the 2
antibodies tested separately. The cytotoxic
reactions of antibodies in admixture were
dependent upon the presence of active
rabbit serum complement.
In a second experiment, using the cross-
reactive human osteogenic sarcoma cell
line 788T, synergistic lysis of target cells
was less evident, although it was increased
3-fold (from 16-2 to 43.4% cytotoxicity)
with anti-791T/36 and anti-791T/48 at 1
and 125,g/ml respectively (Table II). The
findings with 791T and 788T cells indicate
thatthe 2antibodies canactsynergistically
in complement-dependent cytotoxicity
tests, although only within a fairly
narrow range of concentrations.
Effect of source of complement on the cyto-
toxicity of anti-791T monoclonal antibodies
While both anti-791T monoclonal anti-
bodies mediated complement-dependent
cytotoxicity against 791T cells with rabbit
serum complement (Fig. 1 and Tables I
and II), neither anti-791T/36 nor anti-
791T/48 antibody-induced lysis of 791T
cells in the presence of CBA/Ca mouse
serum or human serum (individual or
pooled samples) as complement. In the
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TABLE II.-Synergistic antibody-mediated, complement-dependent cytotoxicity of anti-
791T/36 and anti-791T/48 monoclonal antibodies for osteogenic sarcoma 788T cells.
% cytotoxicity (mean+ s.d.)
Concentration of anti-791T/36 monoclonal antibody (,ig/ml)
,~~~~~~~~~ k
0
0 -1-1+0-8*
(-1-4+0- It)
0-04 0-2 1 5 25
0-0+0-6 -0-3+1-5 12-5+3-3 52-5+3-7 60-2+4-0
0-01; -0-3
0-2 1-1+1-0 0-0+0-6 -0-8+2-4
(1-0+ 1-7)
12-5 52-5 60-2
14-1+2-4 54-0+2-6 58-7+3-6
1-1 1-1 0-8 13-6
1 0-6+0-4 0-0+0-4 0-1+0-8 13-3+5-4
(1-2+ 1-0)
0-6 0-6 0-3 13-1
5 1-2+0-6 0-0+0-1 0-1+ 1-9 13-6+3-2
1-2 1-2
25 1 -9 1 -2 -0- 3+ 1-5
1.9 1-9
125 3-7+0-3 1-9+1-2
(-03 ±+0-4)
3-7 3.7
0-9 13-7
0-8_+12 17-3+5-4
53-6
54-8 + 7-3
53-1
54-0+3-0
(0-6±0-4)
53-7
60-9 + 5.5
1-6 14-4 54-4
4-6+ 1 1 43-4+ 1-5 74-5+6-4
3-4 16-2 56-2
Symbols *, t, t, as footnotes to Table I.
TABLE III.-Complement-dependent cytotoxicity ofanti-791T monoclonal antibodies:
screen ofcomplement sources
% cytotoxicity against
791T cells treated with
Medium Anti-791T/36t Anti-791T/48t
-0- 3+0- 3 53-8+4-7
(-0-2±0-1)§ (0-70-5)
0-3+0-2 0-0+0-2
(0-2±0-3) (-0-1+0-2)
0-0+0-2 0-1+0-1
(-0-1±0-2) (0-5±0-3)
0-0+0-4 0-1+0-2
(00±_0-3) (0-4±0-3)
0-2+0-5 0-2+ 0-1
(0-3±0-2) (-0-2±0-3)
-0-3+0-1 0-1+0-3
(-0-1±0-2) (0-6±0-2)
0-3+0-5 0-1+0-3
(00±_0-5) (-0-1+0-2)
29-1 +2-8
(0-4± 0-6)
0-0+0-1
(0- 3 0-2)
0-1+0-1
(0-3±0-2)
0-4+0-5
(0-7+0-6)
0-3+0-2
(0-1±0-4)
0-4+0-2
(1-0± 0-3)
0-2+0-2
(0-1+0-2)
41
(-
(4
-I
(4
PHA-blasts
treated with
W6/32t Medium W6/32t
6-1+5-3 8-4+0-8 62-3+3-5
0-9+0-5) (-0-4+0-6) (0-0+0-2)
0-0+0-3 0-2+0-7 0-4+1-2
0-1I0-1) (-0-8+0-7) (0-3+0-4)
0-3+0-2 2-1+0-6 76-3+0-9
0-3+0-2) (-0-3+1-0) (0-6+0-9)
0-0+0-4 0-6+0-7 67-6+5-5
0-1+0-1) (0-4±0-3) (0-6±0-6)
0-5+0-2 1-0+1-1 66-4+7-2
06+±0-3) (-0-3+0-7) (1-2+1-2)
0-4+0-3 1-0+1-0 74-8+4-8
0-8+0-2) (-0-6+0-9) (0-7+1-3)
0-5+0-2 1-1+0-4 40-7+4-7
05+±0-1) (-0-1+0-3) (0-1+0-7)
* Final dilution of serum-1/5.
t Anti-791T/36 and anti-791T/48 monoclonal antibodies were tested at a final concentration of 125 tg/ml.
I W6/32 monoclonal antibody was tested at a final dilution of 1/500 of the serum/ascites fluid.
§ Figures in parentheses represent % cytotoxicities determined in the presence of heat-inactivated
complement.
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0
V0
125
64- 8 + 1 -2
(-0-3± 0-4)
64-8
68 -6 + 3 -6
65-9
70-2+ 1 -9
65-4
68-3 + 2-2
66-0
67-3 +4-0
66-7
75-6 + 3*9
(0-3±0-4)
68-5
61-3
61 -9+4-4
60-8
60-9+ 2-6
61-4
66-8 + 3-5
(0-8±1-0)
62-1
73-8+ 1-0
63-9
Serum
source of
complement*
Rabbit
Mouse
Human pool
Human (1)
Human (2)
Human (3)
Guinea-pigM. R. PRICE, M. V. PIMM AND R. W. BALDWIN
positive control tests, rabbit serum (but
not guinea-pig serum) again served as a
potent source of complement and both
monoclonal antibodies produced signifi-
cant cytotoxicity at 125pg/ml (Table III).
To evaluate whether the human, mouse
and guinea-pig sera selected exhibited
complement activity, tests were performed
using the anti-HLA-A, B, C (shared deter-
minant) monoclonal antibody W6/32. As
target cells, 791T tumour cells and PHA-
induced human peripheral blood lympho-
cyte blasts were employed (Table III).
This antibody was cytototoxic for 791T
target cells in the presence ofrabbit serum
complement, but not with mouse, human
or guinea-pig serum. However, lysis of
PHA-induced blasts (40.7-76.3% cyto-
toxicity) was produced by W6/32 using
rabbit, human and guinea-pig serum
complement (but again, not with mouse
serum complement). In all cases, the
cytotoxic reactions were shown to be
complement-dependent, and all cytotoxi-
city values determined in the presence of
heat-inactivated (56°C for 1 h) comple-
ment were between -0-8 and 1.2%
(TableIII). Atthe dilution ofcomplement-
source serum used (final dilution 1/5 in all
tests), there was little or no evidence of
natural cytotoxic activity (due to allo-
or heterophile antibodies) against 791T
cells or PHA-induced blasts, except that
rabbit serum produced a low, comple-
ment-dependent cytotoxicity of8-4 +0.8%
against PHA-induced blasts (Table III).
Lytic activityofserafrom micebear'ing 791T
tumour xenografts
791T tumour cells when injected s.c.
into adult thymectomized, y4irradiated
and cytosine-arabinoside-treated CBA/Ca
mice developed into progressively growing
tumours which kill the recipients after
about 1 month (Pimm et al., 1982). The
sera from these mice were examined for
anti-791T cytotoxic activity and it was
determined that between 35 and 40% of
mice produced potent cytotoxic antibodies
against 791T cells (Fig. 2). All serum
samples were tested at a final dilution of
60
50
40
0
0ll
301
20
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0
0
0
1/40 1/80 1/160
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FIG. 2.-Complement-dependent cytotoxicity
of 791T-xenograft-bearer serum for 791T
tumourtargetcells. Heat-inactivated serum
samples from 30 individual tumour-bearing
mice were tested at a final dilution of 1/80,
and several of the samples (unselected)
were tested additionally at final dilutions
of 1/40 and 1/160. All sera were examined
for cytotoxicity in the presence of heat-
inactivated complement, and in this case
all cytotoxic values were in the range
-0- 4 to 0* 7%. Complement-normal rab-
bit serum at a final dilution of 1/10.
1/80 and some samples (unselected) were
also assayed at 1/40 and 1/160; each of
the cytotoxic reactions was determined
to be complement-dependent and the
cytotoxicity ofnon-tumour-bearer, immu-
nodeprived CBA/Ca mouse serum (6
samples from individual mice and 3 pooled
serum samples) was less than 0.8% at
each of the dilutions examined. However,
the cytotoxicity of these 791T-xenograft-
bearer sera was dependent upon the use
of rabbit and not CBA/Ca mouse serum
as complement (Table IV) and, as shown
in Table V, the cytotoxicity was directed
against the cell lines 791T, 788T and
A549. Since the latter is unreactive with
anti-791T/36 and anti-791T/48 antibodies
(Fig. 1 and Table V), this tumour-bearer
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TABLE IV.-Complement-dependent cytotoxicity of 791T tumour bearer serum (TBS)
for 791T tumour cells using rabbit and mouse serum as complement
Serum
Medium
791T TBS (Z547/1)1
791T TBS (Z547/2)
791T TBS (Z555/1)
Final Percentage cytotoxicity using:
serum r A
dilution Rabbit serum complement* Mouse serum complement*
0-5+0-1 (0-1+0-5)t 0 2±0 2 (0-2+0.4)
1/160 6-5+1-3 (-0-1+0-4) -0-5+0-2 (-0-2+0-2)
1/80 45-9+5-5 (0-0+0-6) -0-1+0-2 (0-1+0-3)
1/80 64-4+1-6 (0-9+0-7) 0-1+0-3 (0-0+0-4)
* Final dilution of serum complement-1/5.
t Figuresinparenthesesrepresent the %cytotoxicity values determined in the presence of heat-inactivated
complement.
I Numbers prefixed by "Z" represent Departmental serum code numbers.
TABLE V.-Complement-dependent cytotoxicity of 791T tumour-bearer serum
for various tumour target cell lines
Serum/antibody c(
Medium
Anti-791T/36
NMS (CBA/Ca)
791T TBS (Z547/1)t
791T TBS (Z547/2)
791T TBS (Z548/5)
Final
dilution/
oncentration
25 ug/ml
5 Ug/ml
1 tg/ml
1/40
1/80
1/160
1/40
1/80
1/160
1/40
1/80
1/160
1/40
1/80
1/160
% cytotoxicity against
791T cells
0-1+0-1 (0.1+0-1)*
40-8+5-1 (0-5+0-4)
34-3 + 2 - 2
30-9 + 4-2
0-8+0-5 (0-2+0-1)
0-3+0- 3
0-1+0-2
25-4+5-1 (0-4+0- 2)
21- 3 + 2 -2
14-3 + 2 -1
64-8 ±4- 7 (0-5+ 0- 3)
58 -3 + 2 - 7
45-3 + 4-7
19.1+2-8 (0-3+0 3)
12.1+3-3
5.0+0 3
788T cells
- 0-3 + 0 2 (-0- 1+ 0-3)
44-6+0-8 (0 4+0 9)
43-8 + 4-5
36-2+4-7
0-5+0-6 (0 2+0 2)
-0 1 +0-6 (-0-4+0 3)
A549 cells
1 - 6 + 0-4 (0 0 0 2)
1-2+0-1 (0-1+0-6)
0-7+0-6
1-4+0-5
1-3+0-2 (0-5+0-1)
1-0+0-3 (0-1+0-4)
24 -5 + 3 -0 (0-3+0-4) 66-6+1-2 (1-9+0-6
0-2 + 0 - 2 (0-2 + 0- 2) 51 - 3 + 1 - 6 (0-5 + 0 - 8
60-7+0-1 (0-40- 6) 50-9+4-8 (1-3+0-2)
50-0+4-1 (0-40-9) 12-9+0-1 (0-2+0-8)
2-9+1-4 (0-3+0-4) 13-1+2-0(030 6)
0-8+0-3 (0-1+0-4) 3-5+0-6 (0-2+0-4)
* Figures in parentheses represent the % cytotoxicity values determined in thepresence ofheat-inactivated
complement (normal rabbit serum, final dilution-1/10).
t Numbers prefixed by "Z" represent Departmental serum code numbers.
cytotoxic response is directed against
determinants other than, or in addition
to, those defined by the 2 anti-791T
monoclonal antibodies.
In vivo reactivity of anti-791T/36 mono-
clonal antibody
791T-xenografted, CBA/Ca mice were
treated with the more potent monoclonal
antibody anti-791T/36, using total ino-
cula of 120 and 240 ,ug/mouse (Figs 3(a)
and (b), respectively) administered in 3
equal intraperitoneal doses on Days 0, 7
and 14. However, the outgrowth of
tumours in treated mice was essentially
equivalent to that in untreated control
animals, and there was no statistically
significant difference in the incidence of
tumours in test mice (8/11) and controls
(10/11) (Fig. 3).
DISCUSSION
The pattern of complement-dependent
cytotoxic reactivity of anti-791T/36 and
anti-791T/48 monoclonal antibodies for
various tumour target cell lines, and using
rabbit serum complement, paralleled that
defined using an 125I-Protein A cell-
binding assay (Embleton et al., 1 9gla. b)
and both antibodies showsodl ma'rimal
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FIG. 3.-Treatment of mice bearing
xenografts by i.p. injection ant
monoclonal antibody. Antibody
jected into mice on days and in
indicated by the arrows. Untrea
served as controls.
reactivity against the immunizi
791T (Fig. 1). In addition, in
the 2 antibodies mediated
killing of 791T and 788T oste
comas, although this was on
within a restricted range of con
(Tables I and II). The synerg
observed were not as pronounc
demonstrated by Hellstr6m el
using 2 anti-melanoma mono(
bodies which together gave up
cytotoxicity at antibody dilut
with either antibody alone hK
no effect. The explanation for
in the melanoma studies the 2
reacted with 2 distinct antig
minants upon the same cell-su
cule, p 97 (Hellstrom et al., 11
anti-osteogenic sarcoma antil
however, considered to be rei
antigenic determinants on se
surface molecules. The patter]
reactions of the 2 antibodies with various
TEST314 tumour target cells are distinct and
clearly distinguishable, suggesting that
CONROLS5/5 they are reactive with separate surface
antigens (Embleton et al., 1981a, b). It is
not clear why synergistic killing occurred
only with mixtures of low concentrations
of anti-791T/36 and high concentrations
of anti-791T/48 antibodies. It is possible
that the antigen defined by anti-791T/48
displays restricted lateral mobility within
----------- the plane ofthe surface membrane so that
it represents a poor target for cytotoxic
reactions which require close proximity
TEST517 of 2 cell-bound IgG antibodies to initiate
ACONROLS 5/6 the complement cascade. The addition of
small quantities of the more cytotoxic
antibody anti-791T/36, defining a more
mobile surface antigen, would then be
expected to enhance cytotoxicity in a
synergistic manner.
30 40 The 2 anti-osteogenic sarcoma mono-
clonal antibodies were not cytotoxic for
s.C. 791T 791T cells using mouse, human or guinea-
li-791T/36 pig serum as complement (Table III).
was ms Mouse complement is known to be both doses as
Lted mice weak and labile so that the failure to
demonstrate cytotoxicity using this source
of complement is not unexpected. Other
ing cell line, studies have demonstrated that normal
admixture or nude mouse serum complement is in-
synergistic effective in mediating lysis compared with
,ogenic sar- rabbit, human or guinea-pig serum (Drake
tly evident et al., 1973; Herlyn & Koprowski, 1981),
centrations although murine IgG2b monoclonal anti-
:istic effects bodies have been shown to fix mouse
-ed as those complement in haemolysis assays (Neu-
t al. (1981) berger & Rajewsky, 1981). In contrast to
clonal anti- the anti-human colon carcinoma mono-
to 70-90% clonal antibodies described by Herlyn &
tions which Koprowski (1981) which utilize human
ad little or complement to effect lysis, the anti-791T
this is that antibodies were non-cytotoxic in the
I antibodies presence of human serum (Table III),
renic deter- although one obvious difference is that
irface mole- the anti-colon carcinoma antibodies belong
981). The 2 to the IgM immunoglobulin class whereas
bodies are, the anti-791T antibodies are IgG2b.
active with Clearly, the human sera tested as com-
,parate cell plement sources were not deficient in this
ns of cross- activity, since PHA-induced blasts were
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lysed by the monoclonal antibody W6/32
andthese human sera complement sources.
However, even this antibody failed to lyse
791T target cells in the presence ofhuman
serum complement and again rabbit serum
complement was required (Table III).
Before attempting therapy of 791T-
xenografted mice using these monoclonal
antibodies, the sera from immunodeprived
tumour-bearing mice were examined for
anti-tumouractivityanditwas determined
that about 30-40% of animals had circu-
lating antibodies which were highly
cytotoxic for 791T target cells (Fig. 2).
This cytotoxic response was not a
"natural" humoral reaction against tu-
mour cells, since non-tumour-bearing
immunodeprived mice did not display
this activity even though T-deprivation
by thymectomy and irradiation has been
reported to increase natural anti-tumour
activity in mice (M6nard et at., 1977;
Colnaghi et al., 1977). The reactivity of
the circulating antibodies was directed
against surface antigens other than, or in
addition to those defined by the anti-
791T monoclonal antibodies since these
antibodies were cytotoxic for the anti-
791T/36 and anti-791T/48-negative cell
line, A549 (Table V). They were not
cytotoxic using mouse complement (Table
IV), so that they would not be expected
to limit tumour growth in vivo by their
cytotoxic reactivity. The presence of
these antibodies in aproportion oftumour-
bearing mice also prevented the type of
therapeutic manipulation attempted by
Herlyn & Koprowski (1981), who adminis-
tered anti-colon carcinoma monoclonal
antibody and rabbit serum as complement
to nude mice bearing tumour xenografts.
The monoclonal antibody anti-791T/36
was selected for the in vivo tests for 3
reasons: at a practical level, it was
available in much greater quantities than
anti-791T/48, it is the more cytotoxic of
the 2 antibodies (Fig. 1) and, finally, tests
performedusingradiolabelledanti-791T/36
have shown that this antibody localizes in
vivo in 791T xenograftsinimmunodeprived
mice (Pimm et A., 1982). The latter
is an essential property if any direct anti-
tumour activity is to be demonstrated
although, as illustrated in Fig. 3, the
administration of anti-791T/36 antibody
to 791T-bearing mice modified neither
tumour development nor incidence. This
finding would also infer that antibody-
dependent cell-mediated cytotoxicity is
inoperativewiththisantibody, tumourand
treatment protocol. Such a mechanism has
been invoked to account for the inhibition
of growth of human colon carcinomas in
nude mice by administration of an anti-
colon carcinoma IgG2a monoclonal anti-
body (Bernstein et al., 1980).
The results of this study demonstrate
that anti-human osteogenic sarcoma 791T
monoclonal antibodies are cytotoxic for
tumour cells in vitro, although the full
expression of their cytotoxicity depends
very much upon the use of rabbit serum
as the source of complement. With regard
to continuing clinical studies which have
demonstratedtumourlocalization ofradio-
labelled anti-791T/36 antibody prepara-
tions by y-scintigraphy, the present
findings predict thatwithtumoursshowing
antibody localization no therapeutic bene-
fit will be produced by complement-
dependent cytotoxicity reactions. How-
ever, antibodies localizing to tumours
may well represent suitable vehicles for
the delivery ofcytotoxic drugs or bacterial
or plant toxins to the site(s) ofthe tumour.
These studies were supported by the Cancer
Research Campaign and by a Government Equip-
ment Grant through the Royal Society.
Thanks are expressed to Dr M. J. Embleton for
making available the human tumour cell lines and
hybridoma supernatants employed in this investiga-
tion, and to Dr R. A. Robins for preparing PHA-
blasts. Skilful technical assistance was provided by
Mrs J. Bullock, Mrs E. Jacobs, Mrs S. J. Gribben and
Mr D. G. Fox.
REFERENCES
BALDWIN, R. W., EMBLETON, M. J. & PRICE, M. R.
(1981) Monoclonal antibodies specifying tumour-
associatedantigens and theirpotentialfortherapy.
Molec. Aspects Med., 4, 329.
BERNSTEIN, I. D., TAM, M. R. & NoWINSKI, R. C.
(1980) Mouse leukemia: therapy with mono-
clonal antibodies against a thymus differentiation
antigen. Science, 207, 68.
COLNAGHI, M. I., MANARD, S. & DELLA PORTA, G.610 M. R. PRICE, M. V. PIMM AND R. W. BALDWIN
(1977) Natural anti-tumour serum reactivity in
BALB/c mice. II. Control by regulator T-cells.
Int. J. Cancer, 19, 275.
DRAKE, W. P., UNGARO, P. C. & MARDINEY, M. R.
(1973) Passive administration of antiserum and
complement in producing anti-EL4 cytotoxic
activity in the serum of C57BL/6 mice. J. Natl
Cancer Inst., 50, 909.
EMBLETON, M. J., GUNN, B., BYERS, V. S. & BALD-
WIN, R. W. (1981a) Antitumour reactions of
monoclonal antibody against a human osteogenic-
sarcoma cell line. Br. J. Cancer, 43, 582.
EMBLETON, M. J., GUNN, B., BYERS, V. & BALDWIN,
R. W. (1981b) Antigens on naturally occurring
animal and human tumors detected by monoclonal
antibodies. Transplant. Proc., 13, 1966.
HELLSTR6M, I., BROWN, J. P. & HELLSTROM, K. E.
(1981) Monoclonal antibodies to two determinants
of melanoma-antigen p 97 act synergistically in
complement-dependent cytotoxicity. J. Immunol.,
127, 157.
HERLYN, D. M. & KOPROWSKI, H. (1981) Monoclonal
anticolon carcinoma antibodies in complement
dependent cytotoxicity. Int. J. Cancer, 27, 769.
HERLYN, D., STEPLEWSKI, Z., HERLYN, M. &
KOPROWSKI, H. (1980) Inhibition of growth of
colorectal carcinoma in nude mice by monoclonal
antibody. Cancer Res., 40, 717.
HUDSON, L. & HAY, F. C. (1980) Practical Immuno-
logy, 2nd Edn. Oxford: Blackwell Sci. Publ. p. 347.
KOHLER, G. & MILSTEIN, C. (1975) Continuous
cultures of fused cells secreting antibody of pre-
defined specificity. Nature, 256, 495.
MANARD, S., COLNAGHI, M. I. & DELLA PORTA, G.
(1977) Natural anti-tumour serum reactivity in
BALB/c mice. I. Characterization and inter-
ference with tumour growth. Int. J. Cancer, 19,
267.
MILLER, R. A., MALONEY, D. G., MCKILLOP, J. &
LEVY, R. (1981) In vivo effects of murine hybri-
doma monoclonal antibody in a patient with T-
cell leukemia. Blood, 58, 1.
NEUBERGER, M. S. & RAJEWSKY, K. (1981). Activa-
tion of mouse complement by monoclonal mouse
antibodies. Eur. J. Immunol., 11, 1012.
PIMM, M. V., EMBLETON, M. J., PERKINS, A. C. & 4
others. (1982) In vivo localization ofanti-osteogenic
sarcoma 791T monoclonal antibody in osteogenic
sarcoma xenografts. Int. J. Cancer, 30, 75.
PRICE, M. R. (1978) A microassay for the detection
of tumour-specific complement-dependent serum
cytotoxicity against a chemically induced rat
hepatoma. Transplantation, 25, 224.
RITZ, J., PESANDO, J. M., SALLAN, S. E. & 4 others
(1981) Serotherapy of acute lymphoblastic leuke-
mia with monoclonal antibody. Blood, 58, 141.
STANWORTH, D. R. & TURNER, M. W. (1978). Immu-
nochemical analysis of immunoglobulins and their
sub-units. In Handbook of Experimental Immuno-
logy (Ed. Weir, 3rd Edn., Vol. 1. Oxford: Black-
well Sci. Publ. p. 6.1.
STEEL, G. G., COURTNEY, V. D. & ROSTOM, A. Y.
(1978) Improved immune suppression techniques
for the xenografting of human tumours. Br. J.
Cancer, 37, 224.